Efalizumab - PDFSEARCH.IO - Document Search Engine

Efalizumab
Results: 7

#	Item
1	Pharmacoepidemiological Research on Outcomes of Therapeutics by a European ConsorTium IMI Work Package 5: Supplement 2 to Wave 1 Case Study Report 1:b:iii: Efalizumab Multi-Criteria Decision Analysis: Decision Add to Reading List Source URL: protectbenefitrisk.eu Language: English - Date: 2014-07-16 01:09:14 Clinical research Immunosuppressants Science Efalizumab Autoimmune diseases Progressive multifocal leukoencephalopathy Psoriasis Placebo Clinical trial Medicine Health Pharmacology
2	Pharmacoepidemiological Research on Outcomes of Therapeutics by a European ConsorTium IMI Work Package 5: Supplement 1 to Wave 1 Case Study Report 1:b:iii: Raptiva® (efalizumab) Add to Reading List Source URL: protectbenefitrisk.eu Language: English - Date: 2014-07-16 01:09:12 Medicine Psoriasis Centocor Health Efalizumab Ustekinumab European Medicines Agency Adalimumab Natalizumab Immunosuppressants Monoclonal antibodies Pharmacology
3	Pharmacoepidemiological Research on Outcomes of Therapeutics by a European ConsorTium IMI Work Package 5: Report 1:b:iii Benefit - Risk Wave 1 Case Study Report: Raptiva® (efalizumab) Add to Reading List Source URL: protectbenefitrisk.eu Language: English - Date: 2014-07-16 01:09:12 Pharmacology Monoclonal antibodies Health Recombinant proteins Efalizumab Adalimumab Psoriatic arthritis Progressive multifocal leukoencephalopathy Biologic Immunosuppressants Medicine Psoriasis
4	Objective is to derive the over all incidence/ prevalence of PML in the USA JCV/PML Reasons for unknown incidence Not reported Add to Reading List Source URL: patients.aan.com Language: English* - Date: 2009-11-10 12:34:40 Immunology Progressive multifocal leukoencephalopathy Natalizumab Rituximab Efalizumab Hematological malignancy Psoriasis JC virus Medicine Immunosuppressants Health
5	FDA Patient Safety News: Show #83, February 2009 Add to Reading List Source URL: www.fda.gov Language: English Pharmaceutical industry Pharmaceutical sciences Pharmacology Clinical research Patient safety Adverse event Efalizumab Package insert MedWatch Medicine Health Food and Drug Administration
6	RAPTIVA® [efalizumab] For injection, subcutaneous WARNING: RISK OF PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML) • RAPTIVA increases the risk for PML, a rapidly progressive viral infection of Add to Reading List Source URL: www.accessdata.fda.gov Language: English - Date: 2009-03-31 14:51:38 Efalizumab Progressive multifocal leukoencephalopathy JC virus Psoriasis Genentech Placebo Sepsis Medicine Health Immunosuppressants
7	RAPTIVA® [efalizumab] For injection, subcutaneous WARNING: RISK OF PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML) • RAPTIVA increases the risk for PML, a rapidly progressive viral infection of Add to Reading List Source URL: www.fda.gov Language: English Efalizumab Progressive multifocal leukoencephalopathy JC virus Psoriasis Genentech Placebo Sepsis Medicine Health Immunosuppressants